Jump to content

Obiltoxaximab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Natureium (talk | contribs) at 05:53, 18 December 2016 (added Category:Experimental drugs using HotCat). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Obiltoxaximab
Monoclonal antibody
Type?
SourceChimeric (mouse/human)
TargetBacillus anthracis anthrax
Clinical data
Trade namesAnthim
ATC code
  • none
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6444H9994N1734O2022S44
Molar mass145.5 kg/mol g·mol−1

Obiltoxaximab is a monoclonal antibody designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).[2]

This drug was developed by Elusys Therapeutics, Inc.

References

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Obiltoxaximab, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Obiltoxaximab&oldid=755469613"